104 related articles for article (PubMed ID: 38747491)
1. Artificial intelligence enhances whole-slide interpretation of PD-L1 CPS in triple-negative breast cancer: A multi-institutional ring study.
Li J; Dong P; Wang X; Zhang J; Zhao M; Shen H; Cai L; He J; Han M; Miao J; Liu H; Yang W; Han X; Liu Y
Histopathology; 2024 May; ():. PubMed ID: 38747491
[TBL] [Abstract][Full Text] [Related]
2. An artificial intelligence-powered PD-L1 combined positive score (CPS) analyser in urothelial carcinoma alleviating interobserver and intersite variability.
Lee KS; Choi E; Cho SI; Park S; Ryu J; Puche AV; Ma M; Park J; Jung W; Ro J; Kim S; Park G; Song S; Ock CY; Choe G; Park JH
Histopathology; 2024 Jul; 85(1):81-91. PubMed ID: 38477366
[TBL] [Abstract][Full Text] [Related]
3. How can artificial intelligence models assist PD-L1 expression scoring in breast cancer: results of multi-institutional ring studies.
Wang X; Wang L; Bu H; Zhang N; Yue M; Jia Z; Cai L; He J; Wang Y; Xu X; Li S; Xiao K; Yan K; Tian K; Han X; Huang J; Yao J; Liu Y
NPJ Breast Cancer; 2021 May; 7(1):61. PubMed ID: 34039982
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores.
Ivanova M; Frascarelli C; Cerbelli B; Pignataro MG; Pernazza A; Venetis K; Sajjadi E; Criscitiello C; Curigliano G; Guerini-Rocco E; Graziano P; Martini M; d'Amati G; Fusco N
Hum Pathol; 2024 Feb; 144():22-27. PubMed ID: 38278450
[TBL] [Abstract][Full Text] [Related]
5. Artificial intelligence-assisted system for precision diagnosis of PD-L1 expression in non-small cell lung cancer.
Wu J; Liu C; Liu X; Sun W; Li L; Gao N; Zhang Y; Yang X; Zhang J; Wang H; Liu X; Huang X; Zhang Y; Cheng R; Chi K; Mao L; Zhou L; Lin D; Ling S
Mod Pathol; 2022 Mar; 35(3):403-411. PubMed ID: 34518630
[TBL] [Abstract][Full Text] [Related]
6. Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer.
Noske A; Wagner DC; Schwamborn K; Foersch S; Steiger K; Kiechle M; Oettler D; Karapetyan S; Hapfelmeier A; Roth W; Weichert W
Breast; 2021 Dec; 60():238-244. PubMed ID: 34768219
[TBL] [Abstract][Full Text] [Related]
7. Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay.
Danziger N; Sokol ES; Graf RP; Hiemenz MC; Maule J; Parimi V; Palmieri C; Pusztai L; Ross JS; Huang RSP
Oncologist; 2023 Apr; 28(4):319-326. PubMed ID: 36866462
[TBL] [Abstract][Full Text] [Related]
8. High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma.
Robert ME; Rüschoff J; Jasani B; Graham RP; Badve SS; Rodriguez-Justo M; Kodach LL; Srivastava A; Wang HL; Tang LH; Troncone G; Rojo F; Van Treeck BJ; Pratt J; Shnitsa I; Kumar G; Karasarides M; Anders RA
Mod Pathol; 2023 May; 36(5):100154. PubMed ID: 36925069
[TBL] [Abstract][Full Text] [Related]
9. Comparison of assessment of programmed death-ligand 1 (PD-L1) status in triple-negative breast cancer biopsies and surgical specimens.
Noske A; Steiger K; Ballke S; Kiechle M; Oettler D; Roth W; Weichert W
J Clin Pathol; 2024 Mar; 77(4):239-245. PubMed ID: 36669878
[TBL] [Abstract][Full Text] [Related]
10. Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey.
Fusco N; Ivanova M; Frascarelli C; Criscitiello C; Cerbelli B; Pignataro MG; Pernazza A; Sajjadi E; Venetis K; Cursano G; Pagni F; Di Bella C; Accardo M; Amato M; Amico P; Bartoli C; Bogina G; Bortesi L; Boldorini R; Bruno S; Cabibi D; Caruana P; Dainese E; De Camilli E; Dell'Anna V; Duda L; Emmanuele C; Fanelli GN; Fernandes B; Ferrara G; Gnetti L; Gurrera A; Leone G; Lucci R; Mancini C; Marangi G; Mastropasqua MG; Nibid L; Orrù S; Pastena M; Peresi M; Perracchio L; Santoro A; Vezzosi V; Zambelli C; Zuccalà V; Rizzo A; Costarelli L; Pietribiasi F; Santinelli A; Scatena C; Curigliano G; Guerini-Rocco E; Martini M; Graziano P; Castellano I; d'Amati G
Crit Rev Oncol Hematol; 2023 Oct; 190():104103. PubMed ID: 37595344
[TBL] [Abstract][Full Text] [Related]
11. A new AI-assisted scoring system for PD-L1 expression in NSCLC.
Huang Z; Chen L; Lv L; Fu CC; Jin Y; Zheng Q; Wang B; Ye Q; Fang Q; Li Y
Comput Methods Programs Biomed; 2022 Jun; 221():106829. PubMed ID: 35660765
[TBL] [Abstract][Full Text] [Related]
12. Interobserver Agreement on the Interpretation of Programmed Death-ligand 1 (PD-L1) Combined Positive Score (CPS) Among Gynecologic Pathologists.
Mills AM; Bennett JA; Banet N; Watkins JC; Kundu D; Pinto A
Am J Surg Pathol; 2023 Aug; 47(8):889-896. PubMed ID: 37272261
[TBL] [Abstract][Full Text] [Related]
13. Artificial Intelligence-Assisted Score Analysis for Predicting the Expression of the Immunotherapy Biomarker PD-L1 in Lung Cancer.
Cheng G; Zhang F; Xing Y; Hu X; Zhang H; Chen S; Li M; Peng C; Ding G; Zhang D; Chen P; Xia Q; Wu M
Front Immunol; 2022; 13():893198. PubMed ID: 35844508
[TBL] [Abstract][Full Text] [Related]
14. Clinical Validation of Artificial Intelligence-Powered PD-L1 Tumor Proportion Score Interpretation for Immune Checkpoint Inhibitor Response Prediction in Non-Small Cell Lung Cancer.
Kim H; Kim S; Choi S; Park C; Park S; Pereira S; Ma M; Yoo D; Paeng K; Jung W; Park S; Ock CY; Lee SH; Choi YL; Chung JH
JCO Precis Oncol; 2024 May; 8():e2300556. PubMed ID: 38723233
[TBL] [Abstract][Full Text] [Related]
15. Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications.
Vainer G; Huang L; Emancipator K; Nuti S
PLoS One; 2023; 18(6):e0285764. PubMed ID: 37267266
[TBL] [Abstract][Full Text] [Related]
16. Artificial intelligence-powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non-small cell lung cancer with better prediction of immunotherapy response.
Choi S; Cho SI; Ma M; Park S; Pereira S; Aum BJ; Shin S; Paeng K; Yoo D; Jung W; Ock CY; Lee SH; Choi YL; Chung JH; Mok TS; Kim H; Kim S
Eur J Cancer; 2022 Jul; 170():17-26. PubMed ID: 35576849
[TBL] [Abstract][Full Text] [Related]
17. A Deep Learning-Based Assay for Programmed Death Ligand 1 Immunohistochemistry Scoring in Non-Small Cell Lung Carcinoma: Does it Help Pathologists Score?
Ito H; Yoshizawa A; Terada K; Nakakura A; Rokutan-Kurata M; Sugimoto T; Nishimura K; Nakajima N; Sumiyoshi S; Hamaji M; Menju T; Date H; Morita S; Bise R; Haga H
Mod Pathol; 2024 Apr; 37(6):100485. PubMed ID: 38588885
[TBL] [Abstract][Full Text] [Related]
18. A Multi-Institutional Study to Evaluate Automated Whole Slide Scoring of Immunohistochemistry for Assessment of Programmed Death-Ligand 1 (PD-L1) Expression in Non-Small Cell Lung Cancer.
Taylor CR; Jadhav AP; Gholap A; Kamble G; Huang J; Gown A; Doshi I; Rimm DL
Appl Immunohistochem Mol Morphol; 2019 Apr; 27(4):263-269. PubMed ID: 30640753
[TBL] [Abstract][Full Text] [Related]
19. Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma.
Huang X; Ding Q; Guo H; Gong Y; Zhao J; Zhao M; Sui D; Wu Y; Chen H; Liu H; Zhang J; Resetkova E; Moulder SL; Wang WL; Huo L
Hum Pathol; 2021 Feb; 108():42-50. PubMed ID: 33221342
[TBL] [Abstract][Full Text] [Related]
20. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.
Rimm DL; Han G; Taube JM; Yi ES; Bridge JA; Flieder DB; Homer R; West WW; Wu H; Roden AC; Fujimoto J; Yu H; Anders R; Kowalewski A; Rivard C; Rehman J; Batenchuk C; Burns V; Hirsch FR; Wistuba II
JAMA Oncol; 2017 Aug; 3(8):1051-1058. PubMed ID: 28278348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
